Algorithm379
In silico Therapeutics

NEWS



29 Sep 2021

New talk from Algorithm379 on advancing in silico drug discovery.







13 Sep 2021

Algorithm379 is happy to share some of the developed code for protein structural analyses. The integrative analytical platform, known as the Fiscore, is  hosted at CRAN and GitHub.




You can get access to the latest version via CRAN and also read our preprint.

 

 



5 July 2021

Algorithm379 study on the c-Rel protein and modulation of NF-kB pathway was selected as a cover for Journal of Biophysical Chemistry, vol 276.




You can get access to the latest issue here




21 June 2021

Algorithm379 announces partnering with Macrogen Europe






You can find more information on Macrogen Europe services here.

 

 

9 June 2021

Algorithm379 partners with the Institute of Entrepreneurship Development





You can find more information on the Institute of Entrepreneurship Development here.



2 June 2021

Algorithm379 presents a novel approach for the immunotherapeutic drug discovery


You can read more here

 


1 June 2021

Algorithm379 partners with Repositive



You can learn more about Repositive’s cancer models, data and services here.




25 May 2021

Algorithm379 partners to discuss "Artificial Intelligence in Drug discovery and Development"


We are very pleased with  the new e-book "Artificial Intelligence in Drug discovery and Development" released by  Repositive. Algorithm379 had an opportunity to partner with Repositive  to shed light on  the machine learning and AI use in the drug discovery and development.

You can get your free copy from the Repositive website.


 




10 May 2021

Our scientific innovation is pushing the limits of new therapeutic target discovery


We are pleased to share our publication discussing new insights into therapeutic targets and biomarkers using integrated multi-‘omics’ approaches for dilated and ischemic cardiomyopathies.











15 April 2021

We have recently discussed the hidden costs of mismanagement in R&D


In order to avoid R&D process mistakes and build good management practices, we have to focus on our research teams and allow them to grow to really unlock their potential. The common pitfalls in management and ways to avoid it are discussed  in our recent opinion piece.